Probing dry-weight improves left ventricular mass index

American Journal of Nephrology

Volumn 33, Issue 4, 2011, Pages 373-380

  Agarwal, Rajiv ^a,b   Bouldin, J Michael ^a   Light, Robert P ^a   Garg, Ashok ^c  

^a Division of Nephrology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Arizona Heart and Arrythmia Clinic   (United States)

Author keywords

Ambulatory blood pressure; Echocardiogram; Hemodialysis; Hypertension; Left ventricular hypertrophy; Left ventricular systolic function; Ultrafiltration; Volume overload

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIALYSIS; DRY WEIGHT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ULTRAFILTRATION; WEIGHT REDUCTION;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS;

EID: 79953035360     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000326235     Document Type: Article

References (27)

1. Kannel WB: Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991; 9:S3-S8.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
3. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
4. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354.
5. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
6. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G: Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: 728-736.
7. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
8. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
9. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
10. Satyan S, Light RP, Agarwal R: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50: 1009-1019.
11. Aurigemma GP, Silver KH, Priest MA, Gaasch WH: Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26: 195-202.
12. Vinch CS, Aurigemma GP, Simon HU, Hill JC, Tighe DA, Meyer TE: Analysis of left ventricular systolic function using midwall mechanics in patients 1 60 years of age with hypertensive heart disease and heart failure. Am J Cardiol 2005; 96: 1299-1303.
13. Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A, Dorhout Mees EJ: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489-1493.
14. Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, Toz H, Can LH, Basci A, Ok E: The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 2009; 24: 956-962.
15. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788.
16. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239.
17. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-664.
18. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881-886.
19. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK: Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
20. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
21. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: 31-37.
22. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
23. Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, Mees EJ: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15: 655-660.
24. Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53: 500-507.
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
26. Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saha C: Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension 2006; 47: 62-68.
27. Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS: In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300.